ALT — Altimmune, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ALT
| date | signal | measured base rate |
|---|---|---|
| 2026-06-22 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-15 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-05-04 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-01 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-23 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-03-30 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-13 | Durso Jerome Benedict President and CEO | Open-market purchase | 15.0K | 2.95 | 44.2K |
| 2026-07-31 | WEAVER GREGORY L Chief Financial Officer | Grant or award | 1.8K | 2.41 | 4.2K |
| 2026-07-31 | Roberts M Scot Chief Scientific Officer | Grant or award | 875 | 2.41 | 2.1K |
| 2026-04-06 | GILL JOHN Director | Open-market purchase | 9.2K | 3.41 | 31.3K |
| 2026-04-01 | Durso Jerome Benedict President and CEO | Open-market purchase | 15.0K | 3.14 | 47.1K |
| 2026-04-01 | WEAVER GREGORY L Chief Financial Officer | Open-market purchase | 10.0K | 3.15 | 31.5K |
| 2026-03-06 | Durso Jerome Benedict President and CEO | Open-market purchase | 20.0K | 3.54 | 70.8K |
| 2026-03-06 | WEAVER GREGORY L Chief Financial Officer | Open-market purchase | 5.0K | 3.54 | 17.7K |
| 2026-02-02 | Roberts M Scot Chief Scientific Officer | Shares withheld for tax | 2.3K | 5.55 | 12.9K |
| 2026-02-02 | Roberts M Scot Chief Scientific Officer | Option exercise | 7.8K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 39.4M | 12.8M |
| STATE STREET CORP | 22.0M | 7.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 17.4M | 5.7M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 16.6M | 5.4M |
| MARSHALL WACE, LLP | 12.4M | 4.0M |
| MILLENNIUM MANAGEMENT LLC | 10.0M | 3.3M |
| GEODE CAPITAL MANAGEMENT, LLC | 9.6M | 3.1M |
| Alyeska Investment Group, L.P. | 8.1M | 2.6M |
| TWO SIGMA INVESTMENTS, LP | 7.6M | 2.5M |
| Nuveen, LLC | 7.2M | 2.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- 9 Health Care Stocks Whale Activity In Today’s Session · 2026-08-14 · benzinga
- Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning · 2026-08-12
- Altimmune GAAP EPS of -$0.12 beats by $0.02 · 2026-08-12
- Altimmune, Inc. (ALT) filed form 8-K · 2026-08-12 · SEC EDGAR
- Altimmune Q2 2026 Earnings Preview · 2026-08-11
Ask the AI about ALT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →